In vitro preclinical models for a rational design of chemotherapy combinations in human tumors

Zoli, Wainer; Ricotti, Luca; Tesei, Anna; Barzanti, F.; Amadori, Dino

doi:10.1016/s1040-8428(00)00110-4

Cited by 69 publications

(66 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although several methods have been proposed to evaluate the interaction between drugs, as critically analysed by Zoli et al (2001), most of these are not applicable to drugs with a low cytotoxic effect. We therefore used Kern's method (Kern et al, 1988), modified by Romanelli (Romanelli et al, 1998), to overcome this problem.…”

Section: Apoptosismentioning

confidence: 99%

Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study

et al. 2007

View full text Add to dashboard Cite

Intravesical gemcitabine (Gem) has shown promising activity against transitional cell carcinomas (TCC) of the bladder, with moderate urinary toxicity and low systemic absorption. The present phase II study evaluated the activity of biweekly intravesical treatment with Gem using a scheme directly derived from in vitro preclinical studies. Patients with Bacille Calmette-Guérin (BCG) -refractory Ta G3, T1 G1-3 TCC underwent transurethral bladder resection and then intravesical instillation with 2000 mg Gem diluted in 50 ml saline solution on days 1 and 3 for 6 consecutive weeks. Thirty-eight (95%) of the 40 patients showed persistent negative post-treatment cystoscopy and cytology 6 months after Gem treatment, while the remaining 2 patients relapsed at 5 and 6 months. At a median follow-up of 28 months, recurrences had occurred in 14 patients. Among these, four had downstaged (T) disease, three had a lower grade (G) lesion and three had a reduction in both T and G. Urinary and systemic toxicity was very low, with no alterations in biochemical profiles. In conclusion, biweekly instillation of Gem proved active in BCG-refractory Ta G3, T1 G1-3 TCC. Our results highlight the importance of preclinical studies using in vitro systems that adequately reproduce the conditions of intravesical clinical treatment to define the best therapeutic schedule.

show abstract

Section: Apoptosismentioning

confidence: 99%

Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Several methods have been proposed to evaluate the interaction between drugs, as critically analyzed by Zoli. 21 However, most of these are not applicable to drugs with a low cytotoxic effect or those lacking dose-response curves, as is the case with Iressa. We therefore used Kern's method 22 subsequently modified by Romanelli 23 to overcome this problem.…”

Section: Methodsmentioning

confidence: 99%

Modulation of drug cytotoxicity by iressa (ZD1839) in pancreatic cancer cell lines

Rosetti

Tesei

Ulivi

et al. 2005

Cancer Biology & Therapy

View full text Add to dashboard Cite

High expression of the epidermal growth factor receptor (EGFR) family confers a growth advantage on malignant cells in various tumor types. Most pancreatic cancers express EGFR, which seems to play an important role in the acquisition of aggressive clinical behaviour and in tumor invasion. Iressa (ZD1839), a quinazoline tyrosine kinase inhibitor selective for the EGF receptor, has shown good anti-tumor activity in both preclinical and clinical studies. Using two pancreatic cancer cell lines that express different EGFR and ErbB-2 levels, we analyzed the activity of Iressa and evaluated its modulation effect on four conventional cytotoxic drugs: gemcitabine, oxaliplatin, docetaxel and SN38. Iressa was tested at scalar doses up to the plasma peak level concentration and showed a similar weak cytostatic effect in both cell lines. Conversely, an additive or weak synergistic effect was observed when the drug was administered simultaneously with or following cytotoxic drugs. Our data show that Iressa has only a weak activity at doses within the plasmatic peak concentration and that its effect is independent of EGFR and p42/p44 expression and phosphorylation levels. This is in agreement with recent literature data that attribute an essential role to a specific EGFR mutation in mediating response to Iressa. This mutation was absent in both pancreatic cell lines tested.

show abstract

“…Which used for magnetic resonance imaging recognition of cancer and induce hyperthermia. It has been documented that an interactive therapy shows synergistic effect, additive effect or antagonistic effect and theranostics [20]. Magnetic nanoparticles coated with polyethene glycol which avoid the identification or capture by reticuloendothelial system, due to opsonin absorbance onto magnetic nanoparticles and phagocytosis carried out by macrophagic cells [21][22].…”

Section:  Antibody Conjugated Magnetic Nanoparticles Induced Hyperthmentioning

confidence: 99%

Development Status in the Meadow of Nanostructure Magnetic Drug Delivery System and Its Promising Applications

Powar

2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

This article discusses about magnetic nanoparticles, their physicochemical properties various applications in medicinal sectors and technology advancements. Superparamagnetic, high magnetic susceptibility, non-toxicity, and biocompatibility and less Curie temperature are critical characteristics of magnetic nanoparticles which make them suitable for assorted medical applications. Now a day's magnetic particles play a significant role in diverse technological areas with potential applications in fields such as electronics, energy biomedicine and diagnosis. Magnetic nanoparticles have been a vivacious topic of extreme research for the last fifty years due to its top-down approaches. The perspective of magnetic nanoparticles stems from the fundamental characteristics of their magnetic cores collective with their drug loading capability, biochemical properties. This article review the modern advancement of magnetic nanoparticles for drug delivery, focusing chiefly on the impending applications like targeted drug delivery, bioseparation, magnetic resonance and cancer diagnosis, induction of hyperthermia, induction of hyperthermia, nanorobotic agents, tissue engineering, artificial muscle, magnetically activated polymers, controlled tissue assembly, control cell function, bone regeneration scaffold, destruction of blood clots, labeling stem cells with magnetic nanoparticles, implant-assisted intrathecal magnetic drug targeting, biodegradable magnetic nano-composite stent, local drug delivery etc.

show abstract

In vitro preclinical models for a rational design of chemotherapy combinations in human tumors

Cited by 69 publications

References 80 publications

Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study

Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study

Modulation of drug cytotoxicity by iressa (ZD1839) in pancreatic cancer cell lines

Development Status in the Meadow of Nanostructure Magnetic Drug Delivery System and Its Promising Applications

Contact Info

Product

Resources

About